RGNX

Regenxbio Inc

7.64

Nov 13 • 3:59 PM ET -0.39 (-4.86%)

7.66

Aftermarket • 6:04 PM ET +0.02 (0.26%)

Healthcare Biotechnology USA Small NASD

Peers: SLDB SRPT FDMT RARE DNLI QURE RCKT DYN TSHA OCGN

| Held by: XBI VTI IWM VXF FESM IBB IWO SCHA VTWO VHT

Scroll to Statements

Index	RUT
Market Cap	505.18M
Enterprise Value	506.20M
Income	-175.23M
Sales	153.91M
Book/sh	2.24
Cash/sh	3.80
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	371
IPO	Sep 17, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	3.28
P/B	3.41
P/C	2.01
P/FCF	-
EV/EBITDA	-
EV/Sales	3.29
Quick Ratio	4.74
Current Ratio	4.74
Debt/Eq	1.70
LT Debt/Eq	1.58
Option/Short	Yes / Yes

EPS (ttm)	-3.21
EPS next Y	-2.75
EPS next Q	-0.96
EPS this Y	22.92%
EPS next Y	4.97%
EPS next 5Y	24.36%
EPS past 3/5Y	16.67% -4.73%
Sales past 3/5Y	14.78% 1.97%
EPS Y/Y TTM	8.03%
Sales Y/Y TTM	-4.59%
EPS Q/Q	47.91%
Sales Q/Q	-69.19%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	51.84% -15.87%

Insider Own	7.51%
Insider Trans	0.90%
Inst Own	66.07%
Inst Trans	4.45%
ROA	-35.36%
ROE	-113.24%
ROIC	-45.91%
Gross Margin	77.79%
Oper. Margin	-120.39%
Profit Margin	-113.85%
SMA20	3.24%
SMA50	-0.21%
SMA200	-13.93%
Trades

Shs Outstand	66.12M
Shs Float	61.16M
Short Float	16.64%
Short Ratio	7.34
Short Interest	10.18M
52W High	16.19 -52.81%
52W Low	5.45 40.05%
Volatility	10.45% 7.32%
ATR (14)	0.59
RSI (14)	50.27
Beta	1.22
Rel Volume	0.52
Avg Volume	1.39M
Volume	716,155

Perf Week	0.26%
Perf Month	6.70%
Perf Quarter	-32.57%
Perf Half Y	33.57%
Perf YTD	-46.94%
Perf Year	-34.36%
Perf 3Y	-56.93%
Perf 5Y	-79.78%
Perf 10Y	-67.21%
Recom	1.36
Target Price	22.36
Prev Close	8.03
Price	7.64
Change %	-4.86%

Consensus

Strong Buy

Avg. Price Target

$22.36

Implied Upside

+192.7%

Analysts14incl. previous ratings

Rating Distribution11 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 05, 2026	Initiated	MMizuho	Outperform	$22	+188.0%
Aug 07, 2026	Downgrade	BBarclays	Overweight → Equal Weight	$12	+57.1%
Jan 28, 2026	Resumed	BBarclays	Overweight	$37	+384.3%
Feb 11, 2025	Downgrade	GGoldman	Buy → Neutral	$38 → $14	+83.2%
Feb 07, 2025	Resumed	RRaymond James	Outperform	$27	+253.4%
Nov 15, 2024	Resumed	MMorgan Stanley	Overweight	$22	+188.0%
Oct 10, 2024	Resumed	RRaymond James	Outperform	$18	+135.6%
Jun 07, 2024	Initiated	GGoldman	Buy	$38	+397.4%
Mar 11, 2024	Initiated	HH.C. Wainwright	Buy	$36	+371.2%
Mar 08, 2024	Upgrade	RRBC Capital Mkts	Sector Perform → Outperform	$20 → $35	+358.1%
Mar 06, 2024	Upgrade	LLeerink Partners	Market Perform → Outperform	$37	+384.3%
Feb 21, 2024	Resumed	RRaymond James	Outperform	$45	+489.0%
Nov 01, 2023	Initiated	SStifel	Buy	$35	+358.1%
Jun 02, 2023	Initiated	RRobert W. Baird	Outperform	$42	+449.7%
Jun 23, 2022	Initiated	BBerenberg	Buy	$61	+698.4%
Dec 15, 2021	Initiated	WWedbush	Neutral	$29	+279.6%
Oct 19, 2021	Resumed	MMorgan Stanley	Overweight	$62 → $50	+554.5%
Jan 06, 2021	Upgrade	RRaymond James	Outperform → Strong Buy	$60	+685.3%
Dec 16, 2020	Initiated	UUBS	Buy	$57	+646.1%
Jun 25, 2020	Resumed	BBofA/Merrill	Buy	$9	+17.8%

Nov-09-26 12:51AM	Mizuho names its top SMID biotech pick for November (Investing.com) +5.91%
Nov-05-26 09:57AM	REGENXBIO's Narrower Loss Leans On A Sarepta Settlement Gain While Investors Wait On The Wet AMD Readout (Earnings Whispers)
07:32AM	Regenxbio: Q3 Earnings Snapshot (Associated Press)
07:05AM	REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
Nov-03-26 07:05AM	REGENXBIO to Participate in Stifel 2026 Healthcare Conference (PR Newswire) +6.56%
12:01PM	Loading…
Oct-29-26 12:01PM	REGENXBIO Faces A Filing Checkpoint As Royalties Shrink And The Stock Slumps (Earnings Whispers)
07:05AM	REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
Oct-12-26 07:05AM	REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 (PR Newswire)
Oct-05-26 09:44AM	Microsoft upgraded, HubSpot downgraded: Wall Street's top analyst calls (The Fly)
07:42AM	Regenxbios Two Lead Gene Therapies Back Mizuhos Nearly 200% Upside Call (Stocktwits)
Sep-25-26 09:37AM	Regenxbio stock gains on positive gene therapy trial data (Investing.com)
Sep-24-26 07:17PM	REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting (PR Newswire)
Sep-16-26 05:30AM	Trump Administration Shift Puts This Corner of Biotech Back in Favor (The Wall Street Journal)
Sep-08-26 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-25-26 07:05AM	REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli (PR Newswire) +10.61%
06:50AM	Loading…
06:50AM	Regenxbios RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street (Stocktwits)
06:21AM	FDA places clinical hold on REGENXBIOs RGX-121 in MPS II trial (Hospital Management)
Aug-24-26 03:18PM	RGNX Stock On Track For Worst Day In Over Three Months BofA Says Buy Despite Disappointing FDA Hold On Gene Therapy (Stocktwits) -24.86%
10:18AM	Why Regenxbio Halted Its Gene Therapy Trial-and Why the Stock Is Tumbling (Barrons.com)
09:02AM	Why Did RGNX Stock Crash Today? (Stocktwits)
08:45AM	REGENXBIO Shares Plunge After FDA Places Clinical Hold on RGX-121 (InvestorsHub)
08:39AM	Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial (Barrons.com)
07:55AM	Safety concerns spur FDA to again halt testing of Regenxbio gene therapy (BioPharma Dive)
07:05AM	REGENXBIO Announces Regulatory Update on RGX-121 for MPS II (PR Newswire)
Aug-06-26 03:02PM	Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ... (GuruFocus.com) +7.43%
07:22AM	Regenxbio: Q2 Earnings Snapshot (Associated Press)
07:05AM	REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
Aug-03-26 07:05AM	REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
Jul-18-26 02:55PM	REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting (PR Newswire)
Jul-17-26 07:00AM	REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants (PR Newswire) -11.70%
06:36PM	Loading…
Jul-16-26 06:36PM	RGNX Stock Slumps 15% After-Hours Whats Driving The Selloff? (Stocktwits) -8.72%
04:26PM	REGENXBIO Announces Proposed Public Offering of Common Stock (PR Newswire)
Jun-29-26 07:05AM	REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone (PR Newswire) +12.88%
Jun-24-26 07:05AM	REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 (PR Newswire)
Jun-23-26 10:26AM	FDA changes rare disease tune again as it clears path for Regenxbios gene therapy (Pharmaceutical Technology) +9.70%
Jun-22-26 11:12AM	AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug \| Stock Movers (Bloomberg) +16.28%
08:44AM	RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbios Hunter Syndrome Therapy (Stocktwits)
07:39AM	Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection (BioPharma Dive)
07:30AM	REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II (PR Newswire)
06:30AM	FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says (The Wall Street Journal)
May-18-26 04:05PM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
May-14-26 07:03PM	Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to ... (GuruFocus.com) -37.80% -8.41%
10:09AM	Regenxbio Shares Rise After Positive Duchenne Trial Results (InvestorsHub)
07:18AM	Regenxbio: Q1 Earnings Snapshot (Associated Press)
07:10AM	REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
07:00AM	REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of RGX-202 (PR Newswire)
05:10AM	With new data, Regenxbio to seek FDA approval of Duchenne gene therapy (BioPharma Dive)
May-07-26 07:05AM	REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting (PR Newswire)
May-06-26 07:05AM	REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy (PR Newswire) +10.85%
Apr-01-26 09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP (PR Newswire)
Mar-30-26 04:06AM	REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX (PR Newswire)
Mar-26-26 09:00AM	SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD (PR Newswire)
Mar-25-26 02:11PM	Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval (Investor's Business Daily) +8.32%
05:01AM	Mixed signals cloud the orphan drug market (Pharma Voice)
Mar-24-26 04:00PM	RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP (Business Wire) -6.35%
Mar-19-26 09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP (PR Newswire)
Mar-17-26 04:00PM	Stephen Pakola Oversaw RGX-111 Safety Claims That Cost RGNX Investors Millions: Levi & Korsinsky, LLP (Business Wire)
Mar-12-26 09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST (PR Newswire)
Mar-11-26 11:45AM	REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX-202 (PR Newswire) -5.25%
09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP (PR Newswire)
Mar-10-26 04:00PM	RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP (Business Wire)
Mar-09-26 04:37PM	This biotech's stock soared after a 'polarizing' FDA official is stepping down (MarketWatch) +20.00%
01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga)
01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal)
08:23AM	uniQure stock surges 36% on FDA officials departure (Investing.com)
Mar-06-26 05:56PM	FDA vaccine chief Vinay Prasad set to leave post next month (Bloomberg)
12:10AM	REGENXBIO Q4 Earnings Call Highlights (MarketBeat)
Mar-05-26 02:25PM	RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST (PR Newswire)
02:02PM	Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience (GuruFocus.com)
08:25AM	Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:23AM	Regenxbio: Q4 Earnings Snapshot (Associated Press Finance)
07:05AM	REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (PR Newswire)
Mar-04-26 09:00AM	REGENXBIO Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RGNX (PR Newswire) +5.18%
07:05AM	REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire)
Mar-03-26 05:30AM	MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines (The Wall Street Journal) -5.95%
Mar-02-26 05:58PM	REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses (PR Newswire)
10:00AM	Adherex Technologies Inc. (FENC) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-26-26 04:06PM	Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug (Investor's Business Daily)
10:00AM	Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-25-26 07:05AM	REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (PR Newswire) +5.57%
Feb-20-26 04:19AM	REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX (PR Newswire)
Feb-17-26 07:30AM	REGENXBIO Inc. Sued for Securities Law Violations Contact the DJS Law Group to Discuss Your Rights RGNX (Business Wire)
Feb-10-26 08:51AM	FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment (Benzinga) -14.16%
06:19AM	FDA rejects Regenxbio treatment in another blow to gene therapy (BioPharma Dive)
05:49AM	REGENXBIO receives FDA response for RGX-121 application (Pharmaceutical Business Review)
Feb-09-26 04:05PM	REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II (PR Newswire)
Feb-02-26 12:18AM	Lost Money on REGENXBIO Inc. (RGNX)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile)
Jan-30-26 06:40AM	Regenxbio (RGNX) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Jan-29-26 10:10AM	Regenxbio selloff an overreaction to clinical hold, says Leerink (TipRanks) +5.36%
Jan-28-26 12:31PM	FDA Clinical Hold Knocks REGENXBIO Stock (Benzinga) -17.90%
09:22AM	The 'Confusing And Unexpected' Update That Slammed Regenxbio Stock (Investor's Business Daily)
07:30AM	REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs (PR Newswire)
06:06AM	Regenxbio gene therapy trials suspended by FDA over safety worries (BioPharma Dive)
Jan-26-26 02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
Jan-19-26 05:20PM	REGENXBIO Inc. (RGNX): A Bull Case Theory (Insider Monkey)
Jan-11-26 03:00PM	REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program (PR Newswire)
Dec-18-25 07:05AM	REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-25-25 07:05AM	REGENXBIO to Participate in Upcoming Investor Conference (PR Newswire) +9.98%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ciongoli Gregory Austin	Director	Aug 27 '26	Buy	9.36	53,407	499,676	118,035	Aug 27 07:03 PM
Ciongoli Gregory Austin	Director	Aug 26 '26	Buy	9.14	49,196	449,706	64,628	Aug 27 07:03 PM
PAKOLA STEVE	Chief Medical Officer	Jul 02 '26	Option Exercise	7.86	2,161	16,985	215,170	Jul 06 04:51 PM
PAKOLA STEVE	Chief Medical Officer	Jul 02 '26	Sale	13.64	2,161	29,476	213,009	Jul 06 04:51 PM
PAKOLA STEVE	Chief Medical Officer	Jul 01 '26	Option Exercise	7.86	36,725	288,658	249,734	Jul 01 08:08 PM
PAKOLA STEVE	Chief Medical Officer	Jul 01 '26	Sale	12.86	36,725	472,284	213,009	Jul 01 08:08 PM
PAKOLA STEVE	Chief Medical Officer	Jun 29 '26	Sale	11.04	19,608	216,472	213,009	Jul 01 08:08 PM
Stephen J. Pakola	Officer	Jul 01 '26	Proposed Sale	11.98	43,206	517,608		Jul 01 04:30 PM
PAKOLA STEVE	Chief Medical Officer	May 11 '26	Sale	11.02	15,309	168,705	232,617	May 13 05:18 PM
STEPHEN PAKOLA	Officer	May 11 '26	Proposed Sale	10.55	34,917	368,374		May 11 04:36 PM
PAKOLA STEVE	Chief Medical Officer	Mar 10 '26	Sale	10.35	5,124	53,033	247,926	Mar 12 06:17 PM
STEPHEN J PAKOLA	Officer	Mar 10 '26	Proposed Sale	10.38	5,124	53,187		Mar 10 04:36 PM
Mills Kenneth T.	Director	Jan 27 '26	Option Exercise	13.09	225,000	2,945,250	707,871	Jan 29 04:58 PM

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

PresidentMr. Curran M. Simpson M.S.

J.D.Mr. Patrick J. Christmas II

Executive VP & Chief Medical OfficerDr. Stephen Pakola M.D.

Executive VP & CFOMr. Mitchell Chan M.B.A.

Executive VP of Product Development & CTOMr. Craig Malzahn

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

RGNX

Regenxbio Inc

Upgrade your Finviz experience

All the Features.
Half the Price.